Immobilizing topoisomerase I on a surface plasmon resonance biosensor chip to screen for inhibitors

[1]  Y. Pommier.  DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition , 2009 .

[2]  Chao-Po Lin,et al.  Proteasome-dependent Processing of Topoisomerase I-DNA Adducts into DNA Double Strand Breaks at Arrested Replication Forks* , 2009, The Journal of Biological Chemistry.

[3]  Katherine S. Yang-Iott,et al.  Formation of dynamic gamma-H2AX domains along broken DNA strands is distinctly regulated by ATM and MDC1 and dependent upon H2AX densities in chromatin. , 2009, Molecular cell.

[4]  S. Moro,et al.  Novel camptothecin derivatives as topoisomerase I inhibitors , 2009, Expert opinion on therapeutic patents.

[5]  A. Chan,et al.  Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity , 2009, Molecules.

[6]  Y. Pommier,et al.  The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. , 2009, Cancer research.

[7]  M. Tanouye,et al.  DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy , 2008, Neuroscience.

[8]  Y. Pommier,et al.  Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity. , 2008, Cancer research.

[9]  T. Herzog,et al.  Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma , 2008, Expert review of anticancer therapy.

[10]  M. Hou,et al.  Studies of sequence-specific DNA binding, DNA cleavage, and topoisomerase I inhibition by the dimeric chromomycin A3 complexed with Fe(II). , 2008, Biochemistry.

[11]  B. Teicher.  Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. , 2008, Biochemical pharmacology.

[12]  A. Shiau,et al.  Back to basics: label-free technologies for small molecule screening. , 2008, Combinatorial chemistry & high throughput screening.

[13]  David G Myszka,et al.  Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. , 2006, Analytical biochemistry.

[14]  Chii-Wann Lin,et al.  Determination of binding constant of DNA-binding drug to target DNA by surface plasmon resonance biosensor technology. , 2005, Current drug targets. Immune, endocrine and metabolic disorders.

[15]  R. Rich,et al.  Survey of the year 2004 commercial optical biosensor literature , 2005, Journal of molecular recognition : JMR.

[16]  J. Doniger,et al.  A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics. , 2004, Antiviral research.

[17]  Jaulang Hwang,et al.  Isodiospyrin as a novel human DNA topoisomerase I inhibitor. , 2003, Biochemical pharmacology.

[18]  Jeremy H. Lakey,et al.  Kinetic analysis of human topoisomerase IIα and β DNA binding by surface plasmon resonance , 2003 .

[19]  A. Tarkowski,et al.  Impact of topoisomerase II inhibition on cytokine and chemokine production , 2003, Inflammation Research.

[20]  R. Lightowlers,et al.  Kinetic analysis of human topoisomerase IIalpha and beta DNA binding by surface plasmon resonance. , 2003, FEBS letters.

[21]  M. Sehested,et al.  Interaction of Human DNA Topoisomerase II α with DNA: Quantification by Surface Plasmon Resonance† , 2002 .

[22]  Lance Stewart,et al.  The mechanism of topoisomerase I poisoning by a camptothecin analog , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[24]  M. Sehested,et al.  Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance. , 2002, Biochemistry.

[25]  V. Nagaraja,et al.  Functional cooperation between topoisomerase I and single strand DNA-binding protein. , 2001, Journal of molecular biology.

[26]  N. Osheroff,et al.  Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. , 2001, Current pharmaceutical design.

[27]  J. Slupsky,et al.  Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. , 2000, Molecular pharmacology.

[28]  G. Loo,et al.  Effects of epigallocatechin gallate and quercetin on oxidative damage to cellular DNA. , 2000, Mutation research.

[29]  D G Myszka,et al.  Survey of the 1998 optical biosensor literature , 1999, Journal of molecular recognition : JMR.

[30]  E. Rogakou,et al.  Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo , 1999, The Journal of cell biology.

[31]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[32]  E C Nice,et al.  Purification of a ligand for the EPH-like receptor HEK using a biosensor-based affinity detection approach. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.